SELLAS Life Sciences Group (NASDAQ:SLS) Sees Unusually-High Trading Volume – Still a Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw unusually-high trading volume on Friday . Approximately 5,343,698 shares were traded during mid-day trading, a decline of 41% from the previous session’s volume of 8,982,878 shares.The stock last traded at $4.5280 and had previously closed at $3.77.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.00.

SELLAS Life Sciences Group Trading Up 10.6%

The stock has a market capitalization of $594.12 million, a P/E ratio of -14.84 and a beta of 2.25. The company has a 50-day moving average price of $1.99 and a 200 day moving average price of $1.87.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. As a group, research analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Katherine Bach Kalin bought 63,400 shares of the stock in a transaction on Wednesday, November 19th. The stock was bought at an average cost of $1.59 per share, for a total transaction of $100,806.00. Following the completion of the purchase, the director directly owned 104,400 shares in the company, valued at approximately $165,996. The trade was a 154.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.40% of the stock is currently owned by company insiders.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors have recently made changes to their positions in the business. Axxcess Wealth Management LLC acquired a new position in shares of SELLAS Life Sciences Group in the 3rd quarter valued at $26,000. BNP Paribas Financial Markets grew its position in SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares during the period. Blair William & Co. IL purchased a new position in SELLAS Life Sciences Group in the second quarter valued at $35,000. ProShare Advisors LLC acquired a new position in shares of SELLAS Life Sciences Group in the second quarter worth about $43,000. Finally, Sei Investments Co. purchased a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter worth about $43,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.